Kornimate/medical-research-clean huggingface dataset:
to study the safety and efficacy of autologous bone marrow stem cells in patients with spinal cord injury

Conditions: Spinal Cord Injury

Summary: this is a phase i/ii, multicenter, prospective, non-randomized, open label study to evaluate the safety/efficacy of autologous bone marrow-derived stem cell transplantation in spinal cord injury patients.

spinal cord injury (sci) is a traumatic disorder resulting in a functional deficit that usually leads to severe and permanent paralysis and the projected data related to the burden of spinal cord injuries across the globe is quite alarming. pharmacological and rehabilitation therapies to sci have got limited effect. there is definitely an urgent need for finding different methods of treatment for these patients who cannot undergo established modalities of treatment or these have been tried unsuccessfully. another promising therapeutic approach for sci is "stem cell transplantation". bone marrow derived stem cells have been shown to promote anatomical and functional recovery in animal models of sci by promoting tissue sparing, axonal regeneration, and remyelination. in our present study, we want to evaluate the safety and efficacy of autologous bone marrow derived stem cells surgically transplanted intrathecally into patients with spinal cord injury.

Eligibility criteria:
inclusion criteria: 1. traumatic injury of the spinal cord (below c5 level) occurring within 6 months to 8 years prior to treatment, resulting in a sustained and complete / partial loss of sensory and motor function below the injury (asia category a, b and c ). 2. confirmation spinal cord injury level (patients with complete or partial transection/damage by mri). 3. those provide fully informed consent. 4. the level of spinal cord injury must be below c4. exclusion criteria: 1. spinal vertebral instability. 2. major concurrent medical illness (e.g. carcinoma, auto-immune disease,) 3. asia impairment scale category other than d \& e. 4. lactating and pregnant women. 5. syringomyelia is also an exclusion criterion but an exemption can be made for a patient with a stable syrinx. 6. platelet count greater than 100 thousand/µl at screening. 7. hematocrit less than 30% prior to bone marrow aspiration. 8. patients with major and current psychiatric illness. 9. significant traumatic brain injury associated with the spinal cord injury.
effect of postoperative ketorolac on bone healing after joint fusion

Conditions: Ketorolac; Joint Fusion

Summary: in the midst of the opioid crisis, the use of non-narcotic pain medication has garnered increased interest, particularly in the field of orthopaedic surgery, where narcotic medications are routinely prescribed postoperatively. nonsteroidal anti-inflammatory drugs (nsaids) have the potential to serve as an adjunct analgesic, but many orthopaedic surgeons have viewed nsaids with hesitancy because of evidence that they can lead to delayed bone healing. when evaluating bone healing across different nsaid formulas, ketorolac was found to cause no delay and lead to better union rates when compared to controls and other nsaids, respectively. previous studies in the orthopaedic spine and trauma literature have suggested a detrimental effect of nsaids, specifically ketorolac, with regards to bone healing, while others have reported no delay in healing. a recent study from our institution found no detrimental effects on the healing of ankle fractures with the use of ketorolac in the immediate postoperative period. additionally, the use of ketorolac was associated with less reliance on narcotic pain medications. the purpose of this prospective randomized study is to evaluate the use of ketorolac on postoperative pain, opioid requirements, patient satisfaction, complication/reoperation rates, and delayed and/or nonunion rates in patients undergoing fusion of their first metatarsophalangeal joint (1st mtpj) for treatment of end-stage arthritis.


Eligibility criteria:
inclusion criteria: * patients over the age of 18 undergoing outpatient primary 1st mtpj fusion by a fellowship-trained foot and ankle orthopaedic surgeon at the rothman orthopaedic institute exclusion criteria: * patients undergoing revision 1st mtpj fusion; * patients with any allergies to any study medication; * patients with documented chronic narcotic use; * patients with renal insufficiency, as defined by history and preoperative creatinine level (cr ≥ 2.1 mg/dl); * patients who are pregnant; * patients undergoing inpatient procedure.
a retrospective real-world study of abemaciclib in hr+ breast cancer

Conditions: Breast Cancer; Neoplasms; Breast Diseases

Summary: the present study will assess real-world clinical outcomes, adverse events and economics from treatment with endocrine therapy(et) combined with abemaciclib in patients with hormone receptor-positive(hr+) breast cancer.

based on clinical trials data, abemaciclib has been approved for early and advanced breast cancer with hr+ and human epidermal growth factor 2 receptor-negative(her2-), but clinical trials require real-world research data as supplementary validation supporting evidence. this study will assess real-world clinical outcomes, adverse events and economics from treatment with endocrine therapy(et) combined with abemaciclib in patients with hr+ breast cancer. in addition, this trial will explore the efficacy of abemaciclib in patients with hr+ and human epidermal growth factor 2 receptor-positive(her2+) breast cancer. this study will now include real-world data on efficacy, toxicity and economics of abemaciclib in the adjuvant setting in hr+ breast cancer. participants to be enrolled will come from an online platform for researches which all the privacy information has been controlled. the investigators are going to gather 2 groups of breast-cancer-one-other-study(bcoos) including bcoos-a and bcoos-b. group bcoos-a includes the patients treated with abemaciclib and letrozole/anastrozole compared with treated with letrozole/anastrozole only. group bcoos-b includes the patients treated with abemaciclib and fulvestrant compared with treated with fulvestrant only. investigators will measure clinical outcomes, adverse events and economics in each group above.

Eligibility criteria:
inclusion criteria: * 18 years or older * histologically confirmed hr-positive breast cancer and imaging/pathological evidence of metastasis is available * treatment with abemaciclib in combination with endocrine therapy * any endocrine therapy * having solid tumor efficacy evaluation criteria recist 1.1 measurable lesions exclusion criteria: * combined with other primary malignancies * associated with serious non-tumor related diseases, such as cardiovascular system, respiratory system, nervous system, blood system, digestive system * pregnant or lactating women * male breast cancer

Keywords: abemaciclib real world study breast cancer
effects of early postoperative showering after coronary artery bypass grafting using bilateral internal thoracic artery

Conditions: Wounds and Injuries; Wound Infection

Summary: the study to evaluate effects of early postoperative showering after coronary artery bypass grafting using bilateral internal thoracic artery


Eligibility criteria:
inclusion criteria: * age \> 18 * patients who underwent coronary bypass grafting with bilateral internal thoracic artery through median sternotomy * patients whose all drains or pacing wires are removed exclusion criteria: * concomitant operation * redo-surgery * prolonged intensive care unit stay (more than 4 days) due to serious complications after surgery * open wounds * active infection * prolonged drains
comparative study between rezum therapy in small and large prostates

Conditions: Prostate Hyperplasia

Summary: the investigators aimed to compare the efficacy and safety of rezūm therapy for the management of benign prostatic hyperplasia (bph) in small and large prostates.

for decades, transurethral resection of the prostate (turp) was the gold standard surgical intervention for small and moderate prostates, however it has high morbidity and prolonged hospital stay rezūm is a radiofrequency made water vapour thermal treatment. it has recently been added to the international guidelines as a choice for medical treatment resistant lower urinary tract symptoms (luts). the aua and canadian urological association (cua) guidelines now add water vapour therapy as a treatment option for bph patients with small prostate size \<80 gm and for those wishing to maintain antegrade ejaculation. while investigators still offer no clear recommendation to rezūm use for those with large prostates.

Eligibility criteria:
inclusion criteria: 1. prostate size 45-75 gm 2. sexually active 3. mod - sever luts 4. q max \< 15 5. ipss \> 15 6. failed medical treatment with alpha blockers exclusion criteria: 1. neurogenic bladder 2. urethral stricture 3. ub stones 4. cancer prostate

Keywords: rezum luts
excessive sweating caused by antidepressants: measurement and treatment with terazosin

Conditions: Hyperhidrosis

Summary: the study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antidepressant. this study is for people who take an antidepressant due to a depressive disorder. this is an open-label study (no placebo group) that will last 5 weeks, with one week of baseline measurement and four weeks of treatment with the study medication. the study is based on the hypothesis that terazosin will be effective in reducing the severity of excessive sweating caused by antidepressant treatment, and will have minimal side-effects.


Eligibility criteria:
inclusion criteria: 1. age 18 - 75 years 2. clinical diagnosis of a depressive disorder (diagnostic and statistical manual of mental disorders - iv-tr) 3. presence of excessive sweating by self-report 4. the excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption 5. treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative 6. excessive sweating has persisted for at least 4 weeks prior to baseline assessment 7. the excessive sweating is rated by the patient as at least moderately bothersome. 8. episodes of excessive sweating occur at least twice a week for last 4 weeks exclusion criteria: 1. presence of another known disease that could potentially cause excessive sweating 2. failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past 3. blood pressure less than 110 mm hg systolic at the screening or baseline visits 4. orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm hg or greater after standing for 2 minutes). 5. current antihypertensive treatment 6. history of significant cardiac disease, including coronary artery disease 7. current use of phosphodiesterase type 5 inhibitors: sildenafil (viagratm), tadalafil (cialistm), or vardenafil (levitratm) 8. history of priapism (persistent and painful erection)

Keywords: depressive disorders excessive sweating sweating caused by antidepressants for those a depressive disorder
platelet-rich plasma for menical tear

Conditions: Platelet-Rich Plasma; Meniscus Lesion

Summary: meniscal injuries are a common pathology among athletes, and have an impact on the daily or sporting practice of patients. surgical approach implies sometimes heavy consequences. platelet-rich-plasma (prp) has been shown to be effective in accelerating wound healing and tissue regeneration in orthopedic and oral surgery. this clinical trial aims to investigate the safety and efficacy of intraarticular and periferal prp injection in patients with stable meniscal injury. the pre- and post-interventional clinical outcomes will be compared.


Eligibility criteria:
inclusion criteria: * skeletally mature patients 18-70 years of age * with diagnosis of meniscus injury * single tear of the medial and/or lateral meniscus * with no indication of meniscus repair surgery exclusion criteria: * prior history of multiple ligaments injury, associated significant ligament instability: grade iii mcl, grade iii pcl, or acl deficient knee * prior history of knee surgery * discoid meniscus * osteoarthritic changes (kellgren lawrence scale \>2) * inflammatory diseases (i.e. rheumatoid arthritis) * underlying bleeding disorder or coagulopathy * concominant chondral defects (\> 2 icrs) * cancer patients * pregnancy * patients who will not cooperate with six-month followup

Keywords: growth factors meniscal injury
dental attire effect on children's dental anxiety

Conditions: Behavior, Child; Dental Anxiety; Anesthesia, Local

Summary: the aim of this study is to evaluate the effect of friendly attire on dental anxiety among children visiting dental office in comparison with conventional attire. all of the children who will be experienced maxillary dental anesthesia with/without distraction will be assessed by using a combination of measures: wong-baker faces and the children's fear scale (self-report), heart pulse rate, and behavior (using anxiety levels using face - legs - activity - cry - consolability "flacc" scale "external evaluator") acceptance will be measured using a two-point likert scale.

this study will evaluate the effect of dental attire on children's acceptance of different dental treatments that include dental anesthesia. pain and anxiety will be evaluated during buccal and palatal infiltration using five behavioral scales, wong-baker pain scale, children's fear scale and children's anxiety questionnaire (self-report), pulse rate (physiological) and behavior (using flacc behavior rating scale "external evaluator". heart pulse rate measurement will be recorded firstly when the patient is seated comfortably in the reception area, on dental chair prior to the injection, and finally after the procedure is done and the child patients will be asked to choose a face that describe their status from one of both wong baker faces scale, children's fear scale and children's anxiety questionnaire. body responses of all child patients will be recorded during the whole procedure and then will be evaluated by an external evaluator to determine the children behavioral score according to flacc scale.

Eligibility criteria:
inclusion criteria: 1. age between 6 and 10 years. 2. no previous dental experience. 3. definitely positive or positive according to frank scale. 4. need of maxillary anesthesia for any dental treatment. exclusion criteria: 1. previous dental experience 2. systematic or mental disorders. 3. definitely negative or negative according to frankel scale

Keywords: dental attire behavior management children fear
low field magnetic stimulation in mood disorders using the lfms device

Conditions: Depression; Bipolar Depression; Major Depressive Disorder

Summary: this study is designed to test whether low-field magnetic stimulation (lfms) can relieve some of the symptoms of depression in bipolar disorder or major depression.

this study involves a screening visit with the study physician and a treatment visit. participants will be asked to complete several questionnaires about their mood during both visits. the treatment visit will involve use of the lfms device. participants will place the top of their head inside the device for approximately 20 minutes. participants will receive either the actual treatment or a sham treatment and will not know which they receive. this device produces weak electromagnetic fields. there is no discomfort or even sensation caused by the device. the device has been declared to be a "non-significant risk device" by the fda, and there are no known risks associated with its use.

Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder or bipolar disorder; must be currently depressed * may be medicated or unmedicated exclusion criteria: * contraindication for mri due to metal in eyes/head * claustrophobia. * inability to lie flat. * history of brain injury. * pregnant * current drug use/abuse/dependence * history of polysubstance use

Keywords: depression major depression bipolar disorder bipolar depression lfms low field magnetic stimulation mood disorders affective disorders
colon cancer prevention using selenium

Conditions: Prevention of Colorectal Cancer

Summary: selenium's ability to prevent colorectal cancer (crc) has been suspected for nearly 30 years, but has never been directly studied in humans. the investigators will directly assess selenium's ability to prevent crc by measuring alterations in aberrant crypt foci (acf), an accepted surrogate marker for crc. acf's are very small (i.e., microscopic) collections of abnormally shaped cells that are a commonly used marker of crc risk. screening colonoscopy at uic routinely uses methods that allow acf counting to be done as a part of standard practice. acf's are not fixed, like polyps or cancers, but can disappear as a person's risk for developing crc decreases. the investigators propose giving patient's with 6 or more acf's 200 mcg selenized yeast or placebo, and determining if there is a drug-dependant decrease in acf number. the primary objective is to determine whether selenized yeast supplementation, compared to placebo, causes significant reduction of acf number from baseline levels. the primary endpoint will be change in acf number


Eligibility criteria:
inclusion criteria: - all non-pregnant patients \>50 years of age exclusion criteria: * the following will be specifically looked for, and result in patients not being eligible for study enrollment: * use of non-steroidal anti-inflammatory drugs or glucocorticosteroids within 60 days of study entry. * history of chronic ibd or prior pelvic radiation (inflammation distorts crypt pattern). * intake of any selenium supplements within 60 days of study entry, including vitamins. * patients with increased bleeding risk from biopsy protocol (i.e. renal failure, decompensated cirrhosis, blood dyscrasia).
network-level mechanisms for preclinical alzheimer's disease development

Conditions: APOE 4

Summary: the purpose of this project is to test the hypothesis that agb101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults. the investigators will compare the functional connectivity results after taking agb101 or placebo.

in this study the investigators want to find out whether the use of a perturbation, such as agb101 low dose of levetiracetam extended release formulation, in healthy adults can reduce abnormal hippocampal network activity. the investigators also want to study whether this low dose of lev can improve memory function. generic levetiracetam is a type of drug called an anti-epileptic or anti-seizure medication. it is fda approved worldwide for adults and children as young as one month with seizures. it is a generic drug used in long-term epilepsy treatment. it is relatively safe and has an acceptable side-effect profile. agb101 has been developed as a novel extended release formulation of low dose levetiracetam (below clinically marketed doses for epilepsy) for slowing the progression of amnestic mild cognitive impairment. it is known that age and the apoe 4 gene are important risk factors for late-onset alzheimer's disease. further studies have shown that cognitively normal, older adults have more hyperfunctional brain network activity, increased alpha beta accumulation, decreased memory function, and decreased brain volume, which is consistent with alzheimer's disease patterns.

Eligibility criteria:
inclusion criteria: * fluent in english * at least eight (8) years of education * geriatric depression scale (gds) (62) score \< 6 * hachinski ischemic score ≤ 4 * normal general cognitive function as well as 1) normal memory function, documented by moca score of 23 or greater, and a rbans delayed memory index score of 85 or greater. exclusion criteria: * neurological disease, such as parkinson's disease, multi-infarct dementia, huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or a history of significant head trauma or known structural brain abnormalities * major psychiatric disease or chronic unstable medical conditions * history of drug abuse * history of alcohol abuse (4 or greater drinks per day on average) * unable to complete mri scans (no pacemaker/defibrillator) * known clinically significant abnormalities in b12 or thyroid function tests * end stage renal disease (esrd) * hemodialysis (hd)

Keywords: healthy adult normal memory apoe 4 brain magnetic resonance imaging mri alzheimer's disease hippocampus genetic testing dementia agb101
optimizing decision making about breast reconstruction after mastectomy: a patient-centered approach

Conditions: Breast Cancer

Summary: although clinical decision tools (cdts) exist for a variety of treatments, cdts designed to support personalized breast reconstruction decisions, particularly about type and timing of reconstruction, are lacking. the objective of this proposal is to develop and pilot test a clinical decision tool that provides personalized risk information and reflects patients' preferences and clinical needs.


Eligibility criteria:
* newly diagnosed or recurrent breast cancer * considering a referral or already referred to a plastic surgeon by their surgical oncologist for possible reconstruction * considering or completing a mastectomy. * does not have known distant metastatic disease (stage iv disease) at the time of recruitment * female. * english-speaking. * at least 18 years of age. * able to understand and willing to sign an irb-approved written informed consent document.
mathematical modeling and risk factor analysis for mortality of sepsis

Conditions: Morality; Risk Factor, Sepsis; Predictive Model

Summary: the purpose of this study was to investigate the risk factors for mortality of sepsis and to create mathematical models to predict the survival rate based on electronic health records that extracted from hospital information system. more than 1000 records should be collected and used to data analysis. univariate and multivariable logistic regression model were applied to risk factors analysis for the outcome, and machine learn algorithms were employed to generate predictive models for the outcome.


Eligibility criteria:
inclusion criteria: * all records with sepsis in emergence department of hospitals exclusion criteria: * subjects with major missing data